A clinical trial to study the beneficial effects of the drug memantine for patients with parkinsonism
Phase 3
Completed
- Conditions
- Health Condition 1: null- ParkinsonismHealth Condition 2: G20- Parkinsons disease
- Registration Number
- CTRI/2016/08/007159
- Lead Sponsor
- SRM University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1)Patients diagnosed with idiopathic PD based on UKPDS Diagnostic Criteria diagnosed Fewer than 7 years
2)Patients Requiring dopaminergic anti-parkinsonism therapy
3)Patients willing to give informed consent
Exclusion Criteria
1)Subjects who are currently treated with apomorphine and/or dopamine receptor antagonists
2)Subjects treated with anticholinergic medications or amantadine alone
3) severe dementia
4)Subjects who have undergone a neurosurgical procedure for PD
5)Subjects who have atypical parkinsonism
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method improvement in parkinsonism and dyskinesias with quality of life assessed by UPDRS, DRS, MMSC, PD quality of life scalesTimepoint: at the end of each month for 1 year
- Secondary Outcome Measures
Name Time Method Improvement in Quality of Life <br/ ><br>improvement in memory functionsTimepoint: at the end of each month for 1 year